Form 4: Kiniksa Pharmaceuticals CEO Sanj K. Patel Executes Stock Option and Sells Shares Under 10b5-1 Plan

Sanj K. Patel, Chairman and CEO of Kiniksa Pharmaceuticals International, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On November 6, 2024, Sanj K. Patel, the Chairman and CEO of Kiniksa Pharmaceuticals International, exercised options to acquire 89,561 Class A Ordinary Shares at a price of $1.59 per share.
• Concurrently, Patel sold 89,561 Class A Ordinary Shares at a weighted average price of $23.
• These transactions were executed under a 10b5-1 trading plan established on April 25, 2024.
• Following these transactions, Patel directly owns 79,551 Class A Ordinary Shares and indirectly owns 109,795 shares through The Marina 2016 Irrevocable Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions were executed under a pre-planned 10b5-1 trading plan and do not necessarily reflect a change in the insider's view of the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions. The use of a 10b5-1 plan suggests that the transactions were pre-planned and not based on any material non-public information. Investors often monitor such filings for insights into management's view of the company's prospects, but in this case, the pre-planned nature of the transactions mitigates the signal.

Key Dates